Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Tirzepatide · Mounjaro, Zepbound

Peptide · Agonist of GIP receptor (GIPR) and GLP-1 receptor (GLP1R) · developed by Eli Lilly And Co

Approved FDA, May 2022
LLY Developer
2 Registered trials

What is Tirzepatide?

Tirzepatide is a peptide that selectively binds and activates both the GIP and GLP-1 receptors, the targets of the native incretin hormones. It carries a C20 fatty diacid that enables albumin binding and prolongs its half-life. It is studied in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Mounjaro, Zepbound, LY-3298176, BG-121
Drug type
Peptide
Targets
GIP receptor (GIPR), GLP-1 receptor (GLP1R)
Mechanism
Agonist of GIP receptor (GIPR) and GLP-1 receptor (GLP1R)
Pathways
GIP and GLP-1 receptor activation, appetite regulation and food intake control in the brain, glycemic control
Therapy area
Gastroenterology
Developer
Eli Lilly And Co (LLY)
Also in trials of
LEXX
FDA status
Approved as Mounjaro, Zepbound (May 13, 2022), NDA215866 · FDA label
UNII
OYN3CCI6QE

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 28, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07165028 Phase 3 Metabolic Dysfunction-Associated Steatotic Liver Disease Recruiting LLY
NCT06648031 Phase 1 Type2diabetes Completed LEXX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metabolic Dysfunction-Associated Steatotic Liver DiseaseType2diabetes

Other drugs acting on GIPR / GLP1R

Dulaglutide FDA approved Orforglipron FDA approved Semaglutide FDA approved Avexitide Phase 3 DehydraTECH-semaglutide Phase 1 LY3537021 Phase 2 Maridebart Cafraglutide Phase 3 VK2735 Investigational

More from Eli Lilly And Co

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Brenipatide Phase 3 Clazakizumab Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Tirzepatide

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.